JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia

被引：63

作者：

Kraemer, Alwin

Reiter, Andreas

Kruth, Jens

Erben, Philipp

Hochhaus, Andreas

Mueller, Martin

Cross, Nicholas C. P.

Jones, Amy V.

Ho, Anthony D.

Hensel, Manfred

机构：

[1] Univ Heidelberg, Dept Internal Med 5, D-69120 Heidelberg, Germany

[2] Univ Heidelberg, Fac Clin Med Mannheim, Dept Internal Med 3, Mannheim, Germany

[3] Wessex Reg Genet Lab, Salisbury, Wilts, England

来源：

LANCET ONCOLOGY | 2007年 / 8卷 / 07期

关键词：

D O I：

10.1016/S1470-2045(07)70206-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：658 / 660

页数：3

共 16 条

[1] Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [J].

Baxter, EJ ;

Scott, LM ;

Campbell, PJ ;

East, C ;

Fourouclas, N ;

Swanton, S ;

Vassiliou, GS ;

Bench, AJ ;

Boyd, EM ;

Curtin, N ;

Scott, MA ;

Erber, WN ;

Green, AR .

LANCET, 2005, 365 (9464) :1054-1061

[2] Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis [J].

Beham-Schmid, C ;

Apfelbeck, U ;

Sill, H ;

Tsybrovsky, O ;

Höfler, G ;

Haas, OA ;

Linkesch, W .

BLOOD, 2002, 99 (01) :381-383

[3] The Philadelphia translocation and pre-existing myeloproliferative disorders [J].

Curtin, NJ ;

Campbell, PJ ;

Green, AR .

BRITISH JOURNAL OF HAEMATOLOGY, 2005, 128 (05) :734-736

[4] Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR [J].

Emig, M ;

Saussele, S ;

Wittor, H ;

Weisser, A ;

Reiter, A ;

Willer, A ;

Berger, U ;

Hehlmann, R ;

Cross, NCP ;

Hochhaus, A .

LEUKEMIA, 1999, 13 (11) :1825-1832

[5] A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q 11.2) translocation in a patient with a clinically typical chronic myeloid leukemia [J].

Griesinger, F ;

Hennig, H ;

Hillmer, F ;

Podleschny, M ;

Steffens, R ;

Pies, A ;

Wörmann, B ;

Haase, D ;

Bohlander, SK .

GENES CHROMOSOMES & CANCER, 2005, 44 (03) :329-333

[6] A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera [J].

James, C ;

Ugo, V ;

Le Couédic, JP ;

Staerk, J ;

Delhommeau, F ;

Lacout, C ;

Garçon, L ;

Raslova, H ;

Berger, R ;

Bennaceur-Griscelli, A ;

Villeval, JL ;

Constantinescu, SN ;

Casadevall, N ;

Vainchenker, W .

NATURE, 2005, 434 (7037) :1144-1148

[7] JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia [J].

Jelinek, J ;

Oki, Y ;

Gharibyan, V ;

Bueso-Ramos, C ;

Prchal, JT ;

Verstovsek, S ;

Beran, M ;

Estey, E ;

Kantarjian, HM ;

Issa, JPJ .

BLOOD, 2005, 106 (10) :3370-3373

[8] Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha [J].

Jones, AV ;

Silver, RT ;

Waghorn, K ;

Curtis, C ;

Kreil, S ;

Zoi, K ;

Hochhaus, A ;

Oscier, D ;

Metzgeroth, G ;

Lengfelder, E ;

Reiter, A ;

Chase, AJ ;

Cross, NCP .

BLOOD, 2006, 107 (08) :3339-3341

[9] Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders [J].

Jones, AV ;

Kreil, S ;

Zoi, K ;

Waghorn, K ;

Curtis, C ;

Zhang, LY ;

Score, J ;

Seear, R ;

Chase, AJ ;

Grand, FH ;

White, H ;

Zoi, C ;

Loukopoulos, D ;

Terpos, E ;

Vervessou, EC ;

Schultheis, B ;

Emig, M ;

Ernst, T ;

Lengfelder, E ;

Hehlmann, R ;

Hochhaus, A ;

Oscier, D ;

Silver, RT ;

Reiter, A ;

Cross, NCP .

BLOOD, 2005, 106 (06) :2162-2168

[10] A gain-of-function mutation of JAK2 in myeloproliferative disorders [J].

Kralovics, R ;

Passamonti, F ;

Buser, AS ;

Teo, S ;

Tiedt, R ;

Passweg, JR ;

Tichelli, A ;

Cazzola, M ;

Skoda, RC .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (17) :1779-1790

← 1 2 →